Results 11 to 20 of about 1,008,618 (142)

A novel and simple method for rapid generation of recombinant porcine adenoviral vectors for transgene expression. [PDF]

PLoS ONE, 2015
Many human (different serotypes) and nonhuman adenovirus vectors are being used for gene delivery. However, the current system for isolating recombinant adenoviral vectors is either time-consuming or expensive, especially for the generation of ...
Peng Zhang, Enqi Du, Jing Ma, Wenbin Wang, Lu Zhang, Suresh K Tikoo, Zengqi Yang   +6 more
doaj   +2 more sources

Adenoviral Vector Expressing ICP47 Inhibits Adenovirus-Specific Cytotoxic T Lymphocytes in Nonhuman Primates

Molecular Therapy, 2000
Studies from several laboratories have shown that administration of E1-deleted Ad vectors results only in transient transgene expression in the lungs of immunocompetent animals. This is due, at least in part, to destruction of vector-transduced cells by host cellular immune responses (predominantly CD8(+) CTLs) directed against viral proteins and/or ...
Abraham Scaria, Samuel C Wadsworth, Richard J Gregory   +2 more
exaly   +3 more sources

Immunization route-mediated differences in long-term maturation of humoral immune response induced by adenovirus vector-based COVID-19 vaccine Sputnik V in nonhuman primates [PDF]

Frontiers in Immunology
IntroductionOn the background of kaleidoscopic changes of SARS-CoV-2 circulating variants, constant presence of SARS-CoV-2 in the human population hampers the dissection of native long-term immunogenicity of COVID-19 vaccines.MethodsFor this purpose, we ...
Amir I. Tukhvatulin, Ilya V. Gordeychuk, Ilya V. Gordeychuk, Alina S. Dzharullaeva, Inna V. Dolzhikova, Ekaterina O. Bayurova, Fatima M. Izhaeva, Anna V. Kovyrshina, Alla S. Zhitkevich, Daria V. Avdoshina, Stanislav A. Gulyaev, Tatiana V. Gulyaeva, Andrey V. Moroz, Ilias B. Esmagambetov, Ilya D. Zorkov, Anna A. Iliukhina, Artem Y. Shelkov, Alina S. Erokhova, Dmitry V. Shcheblyakov, Olga V. Zubkova, Aydar A. Ishmukhametov, Aydar A. Ishmukhametov, Denis Y. Logunov, Denis Y. Logunov, Alexander L. Gintsburg, Alexander L. Gintsburg   +25 more
doaj   +2 more sources

Adenoviral Vector-Based Vaccine Expressing Hemagglutinin Stem Region with Autophagy-Inducing Peptide Confers Cross-Protection Against Group 1 and 2 Influenza A Viruses

Vaccines
Background/Objectives: An effective universal influenza vaccine is urgently needed to overcome the limitations of current seasonal influenza vaccines, which are ineffective against mismatched strains and unable to protect against pandemic influenza ...
Wen-Chien Wang, Ekramy E. Sayedahmed, Marwa Alhashimi, Ahmed Elkashif, Vivek Gairola, Muralimanohara S. T. Murala, Suryaprakash Sambhara, Suresh K. Mittal   +7 more
doaj   +3 more sources

A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV-Important Lessons Learned. [PDF]

J Med Primatol
ABSTRACT Background In a randomized, blinded, dual center study across two European primate research facilities, we evaluated the immunogenicity and protective efficacy of a DNA prime—oropharyngeal adenoviral boost vaccination strategy against respiratory syncytial virus (RSV).
Tenbusch M, Koopman G, Mooij P, Roshani B, Irrgang P, Lapuente D, Kondova I, Bogers WM, Remarque EJ, Vestweber R, Merida Ruiz SA, Krüger N, Meyer S, Gefeller O, Stahl-Hennig C, Überla K.   +15 more
europepmc   +2 more sources

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives. [PDF]

MedComm (2020)
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Yang M, Song Y, Wang Z, Chao K, Li L, Zhang X, Duan X, Yu C, Xue R, Zhao J.   +9 more
europepmc   +2 more sources

Sex Differences in Response to Viral Vector Vaccines-Implications for Future Vaccine Design. [PDF]

Immunol Rev
ABSTRACT Vaccination represents one of the most impactful public health achievements, preventing 3.5 to 5 million deaths annually according to estimates of the World Health Organization. Yet, recent outbreaks of emerging and reemerging infectious diseases highlight the need for rapid and strategic vaccine development using vaccine platforms ...
Grewe I, Zoran T, Addo MM.
europepmc   +2 more sources

Marburg Virus Glycoprotein Is a Remarkable Virulent Factor Linked to Hemorrhagic Pathology: Evidence from Multimodal Experimental Systems. [PDF]

Adv Sci (Weinh)
By integrating data from in vitro, ex vivo, and in vivo models, our research identifies the MARV glycoprotein as a remarkable hemorrhagic factor, filling a major gap in this important field. It also provides practical experimental tools for the basic research on viral pathogenesis and applied research aimed at antiviral intervention for hemorrhagic ...
Yao T, Liu H, Yao Y, Deng W, Sun J, Kang Z, Ali A, Shan C, Yuan Z, Deng F, Wang H, Ning YJ.   +11 more
europepmc   +2 more sources

Activation of Innate Immunity in Nonhuman Primates Following Intraportal Administration of Adenoviral Vectors

Molecular Therapy, 2001
The innate immune response to intraportally infused adenoviral vector was evaluated in rhesus monkeys. A first-generation adenovirus-expressing lacZ (Ad-lacZ) was administered at a dose just below that which causes severe morbidity. The response to vector was evaluated for the initial 24 h following infusion.
Schnell, Michael A., Zhang, Yi, Tazelaar, John, Gao, Guang-ping, Yu, Q.C., Qian, Ruth, Chen, Shu-Jen, Varnavski, Andrei N., LeClair, Cynthia, Raper, Steven E., Wilson, James M.   +10 more
openaire   +2 more sources

Gene therapy for epilepsy: An emerging, promising approach for a serious neurological disorder. [PDF]

J Intern Med
Abstract Gene therapy is emerging as a groundbreaking strategy for treating epilepsy, offering new hope to patients who do not respond to conventional medications. Despite advancements in anti‐seizure treatments, nearly 30%–40% of individuals with epilepsy continue to experience uncontrolled seizures, highlighting the urgent need for more effective and
Ledri M, Kokaia M.
europepmc   +2 more sources